EGFR and non-small cell lung carcinoma: A phase I/II dose-escalation study of osimertinib (AURA, NCT01802632) was carried out in patients with locally advanced or metastatic EGFR-mutated NSCLC progressing on first- or second-generation EGFR TKIs.